Sign in or create an account to add this stock to your watchlist.
About IRadimed (NASDAQ:IRMD)
IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022
Debt
Debt-to-Equity RatioN/A
Current Ratio9.19
Quick Ratio8.10
Price-To-Earnings
Trailing P/E Ratio230.63
Forward P/E Ratio57.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.08 million
Price / Sales8.52
Cash Flow$0.2154 per share
Price / Cash85.64
Book Value$3.21 per share
Price / Book5.75
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins6.29%
Return on Equity6.27%
Return on Assets5.32%
Miscellaneous
Employees83
Outstanding Shares10,660,000
IRadimed (NASDAQ:IRMD) Frequently Asked Questions
What is IRadimed's stock symbol?
IRadimed trades on the NASDAQ under the ticker symbol "IRMD."
How will IRadimed's stock buyback program work?
IRadimed announced that its Board of Directors has approved a stock buyback plan on Sunday, June 4th 2017, which permits the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its shares are undervalued.
How were IRadimed's earnings last quarter?
IRadimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Monday, April, 30th. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.04. The medical equipment provider earned $7.11 million during the quarter, compared to the consensus estimate of $6.83 million. IRadimed had a return on equity of 6.27% and a net margin of 6.29%. View IRadimed's Earnings History.
When is IRadimed's next earnings date?
What price target have analysts set for IRMD?
2 brokers have issued 12-month price objectives for IRadimed's shares. Their forecasts range from $16.00 to $19.00. On average, they anticipate IRadimed's share price to reach $17.50 in the next year. View Analyst Ratings for IRadimed.
Who are some of IRadimed's key competitors?
Some companies that are related to IRadimed include AngioDynamics (ANGO), Tandem Diabetes Care (TNDM), SurModics (SRDX), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Endologix (ELGX), Inovio Pharmaceuticals (INO), RenovaCare (RCAR), GenMark Diagnostics (GNMK), Utah Medical Products (UTMD), Antares Pharma (ATRS), Accuray (ARAY), Westaim (WEDXF), Cytosorbents (CTSO) and T2 Biosystems (TTOO).
Who are IRadimed's key executives?
IRadimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 65)
- Mr. Christopher K. Scott, CFO & Sec. (Age 48)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 59)
- Mr. John McCreery, Chief Operating Officer (Age 63)
- Mr. Louis Waldman, Controller (Age 63)
Has IRadimed been receiving favorable news coverage?
Media stories about IRMD stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IRadimed earned a media sentiment score of 0.13 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 43.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are IRadimed's major shareholders?
IRadimed's stock is owned by many different of institutional and retail investors. Top institutional investors include Mondrian Investment Partners LTD (1.86%), Boston Partners (0.70%), Russell Investments Group Ltd. (0.55%), Granite Investment Partners LLC (0.34%), Spark Investment Management LLC (0.29%) and Northern Trust Corp (0.25%). Company insiders that own IRadimed stock include Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for IRadimed.
Which institutional investors are selling IRadimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Mondrian Investment Partners LTD and Spark Investment Management LLC. Company insiders that have sold IRadimed company stock in the last year include Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for IRadimed.
Which institutional investors are buying IRadimed stock?
IRMD stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Russell Investments Group Ltd., O Shaughnessy Asset Management LLC and Northern Trust Corp. View Insider Buying and Selling for IRadimed.
How do I buy shares of IRadimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRadimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $18.45.
How big of a company is IRadimed?
IRadimed has a market capitalization of $196.60 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. IRadimed employs 83 workers across the globe.
How can I contact IRadimed?
IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for IRadimed (IRMD)
MarketBeat's community ratings are surveys of what our community members think about IRadimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
IRadimed (NASDAQ:IRMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for IRadimed in the last 12 months. Their average twelve-month price target is $17.50, suggesting that the stock has a possible downside of 5.15%. The high price target for IRMD is $19.00 and the low price target for IRMD is $16.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.50 | $17.50 | $17.50 | $17.50 |
| Price Target Upside: | 5.15% downside | 29.63% upside | 29.63% upside | 29.63% upside |
IRadimed (NASDAQ:IRMD) Consensus Price Target History
IRadimed (NASDAQ:IRMD) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/27/2017 | Credit Suisse Group | Initiated Coverage | Buy | $19.00 | Low |  |
| 10/31/2017 | Roth Capital | Initiated Coverage | Buy ➝ Buy | $16.00 | N/A | |
(Data available from 5/27/2016 forward)
IRadimed (NASDAQ:IRMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IRadimed (NASDAQ IRMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 61.20%
Institutional Ownership Percentage: 17.40%
IRadimed (NASDAQ IRMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/4/2018 | Louis S. Waldman | Insider | Sell | 5,221 | $18.19 | $94,969.99 | | |
| 5/2/2018 | Monty K Allen | Director | Sell | 1,899 | $17.94 | $34,068.06 | 19,972 | |
| 3/16/2018 | Louis S Waldman | Insider | Sell | 30,000 | $13.83 | $414,900.00 | 5,221 | |
| 3/16/2018 | Roger E Susi | CEO | Buy | 1,000 | $13.85 | $13,850.00 | 21,000 | |
| 12/4/2017 | Monty K Allen | Director | Sell | 1,898 | $13.95 | $26,477.10 | 9,062 | |
| 6/1/2017 | Steven M Nardi | VP | Sell | 4,634 | $8.32 | $38,554.88 | 2,194 | |
| 2/9/2017 | Roger E Susi | CEO | Buy | 10,000 | $8.60 | $86,000.00 | 15,000 | |
| 11/29/2016 | Roger E Susi | CEO | Buy | 5,000 | $11.24 | $56,200.00 | 10,000 | |
| 11/15/2016 | Roger E Susi | CEO | Buy | 5,000 | $10.46 | $52,300.00 | 5,000 | |
| 8/16/2016 | Steven M Nardi | VP | Sell | 2,096 | $17.11 | $35,862.56 | 1,996 | |
| 6/14/2016 | Monty K. Allen | Director | Sell | 2,275 | $20.00 | $45,500.00 | | |
| 6/13/2016 | Monty K Allen | Director | Sell | 2,100 | $20.44 | $42,924.00 | 4,375 | |
| 2/19/2016 | Serge Novovich | Director | Sell | 2,910 | $17.23 | $50,139.30 | 107,546 | |
| 2/18/2016 | Steven M Nardi | VP | Sell | 192 | $17.00 | $3,264.00 | 2,288 | |
| 12/23/2015 | Roger E Susi | CEO | Sell | 156,521 | $23.28 | $3,643,808.88 | | |
| 12/18/2015 | Roger E Susi | CEO | Sell | 1,043,479 | $23.28 | $24,292,191.12 | | |
| 12/16/2015 | Steven M. Nardi | VP | Sell | 4,438 | $26.80 | $118,938.40 | 100 | |
| 12/8/2015 | Brent Johnson | VP | Sell | 22,659 | $30.92 | $700,616.28 | | |
| 12/7/2015 | Steven M. Nardi | VP | Sell | 624 | $31.02 | $19,356.48 | 600 | |
| 12/4/2015 | Brent Johnson | VP | Sell | 400 | $31.51 | $12,604.00 | | |
| 12/3/2015 | Brent Johnson | VP | Sell | 26,880 | $31.52 | $847,257.60 | | |
| 12/1/2015 | Serge Novovich | Director | Sell | 1,000 | $31.12 | $31,120.00 | 100,983 | |
| 11/25/2015 | James B. Hawkins | Director | Sell | 5,290 | $30.98 | $163,884.20 | 83,460 | |
| 8/25/2015 | Monty K. Allen | Director | Sell | 6,250 | $24.85 | $155,312.50 | | |
| 12/29/2014 | Steven M Nardi | VP | Buy | 2,100 | $12.58 | $26,418.00 | | |
| 7/21/2014 | James B Hawkins | Director | Buy | 80,000 | $6.25 | $500,000.00 | | |
(Data available from 1/1/2013 forward)
IRadimed (NASDAQ IRMD) News Headlines
| Source: |
|
IRadimed (NASDAQ:IRMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IRadimed (NASDAQ:IRMD) Income Statement, Balance Sheet and Cash Flow Statement
IRadimed (NASDAQ IRMD) Stock Chart for Sunday, May, 27, 2018
Loading chart…
